<DOC>
	<DOCNO>NCT03017404</DOCNO>
	<brief_summary>To study maximum tolerate dose Doxorubicin Hydrochloride Liposome Injection combination cyclophosphamide sequential treatment docetaxel patient locally advance breast cancer</brief_summary>
	<brief_title>A Dose Increase Finding Study Doxorubicin Hydrochloride Liposome Injection Patients With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Female patient newly diagnose breast cancer≥18 ≤70 year age ; Karnofsky performance status≥70 measurable evaluable ; Stages ⅢaⅢC ; Baseline leave ventricular ejection fraction ( LVEF ) ≥ 50 % ; Adequate marrow function ( WBC count＞ 4.0×10 ( 9 ) /L , neutrophil＞ 2.0×10 ( 9 ) /L , platelet count ＞ 100×10 ( 9 ) /L，hemoglobin ＞ 90g/L ) ; AST ALT ≤1.5× institutional upper limit normal , alkaline phosphatase ≤2.5×institutional upper limit normal，bilirubin ≤institutional upper limit normal ; Serum creatinine ≥ 44µmol/L ≤ 133 µmol/L ; Expected lifetime ≥ 12 month ; Pregnancy test reproductive age woman negative ; All patient provide write informed consent . Distant metastasis ; Severe heart failure ( NYHA grade II high ) ; Active uncontrolled severe infection ; Hypersensitivity anthracycline therapy history severe hypersensitivity reaction product contain liposomal doxorubicin docetaxel ; Have accept antitumor drug within 30 day first dose doxorubicin hydrochloride liposome doxorubicin ; Pregnancy breast feeding ; Other situation investigator consider contraindication study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>